
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBP-307 (icanbelimod) is an once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary endpoint of change from baseline on adapted Mayo Score for CBP-307 0.2 mg once-daily, orally administered dose showed a numerical improvement, but did not achieve statistical significance.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 03, 2022
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBP-307 orally available, next generation small molecule modulator of the sphingosine-1-phosphate 1 receptor, G-protein coupled receptor plays role in regulating T cell movement out of lymph nodes and into the periphery and is a validated therapeutic ta...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 19, 2021
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : CBP-307
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study On Human Mass Balance And Biotransformation
Details : CBP-307 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 10, 2021
Lead Product(s) : CBP-307
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBP-307 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Autoimmune Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2021
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBP-307 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2021
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307
Details : Novel, next-generation S1P1 agonist currently in Phase 2 clinical development for treatment of inflammatory bowel disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2020
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Tigermed | Nucleus Network
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Study Accessing the Safety and Tolerability of CBP-307
Details : CBP-307 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Autoimmune Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2014
Lead Product(s) : CBP-307
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Tigermed | Nucleus Network
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All